全文获取类型
收费全文 | 121篇 |
免费 | 0篇 |
国内免费 | 1篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 4篇 |
内科学 | 4篇 |
神经病学 | 1篇 |
特种医学 | 4篇 |
外科学 | 8篇 |
预防医学 | 10篇 |
药学 | 1篇 |
肿瘤学 | 88篇 |
出版年
2024年 | 1篇 |
2022年 | 3篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 7篇 |
2018年 | 5篇 |
2017年 | 5篇 |
2016年 | 1篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 13篇 |
2012年 | 9篇 |
2011年 | 6篇 |
2010年 | 8篇 |
2009年 | 3篇 |
2008年 | 2篇 |
2007年 | 5篇 |
2006年 | 10篇 |
2005年 | 6篇 |
2004年 | 8篇 |
2003年 | 8篇 |
2002年 | 5篇 |
2001年 | 4篇 |
1999年 | 1篇 |
1998年 | 2篇 |
排序方式: 共有122条查询结果,搜索用时 46 毫秒
111.
Timmer-Bonte JN Punt CJ vd Heijden HF van Die CE Bussink J Beijnen JH Huitema AD Tjan-Heijnen VC 《Lung cancer (Amsterdam, Netherlands)》2008,60(2):222-230
In advanced non-small cell lung cancer (NSCLC) the clinical benefit of a platinum-based doublet is only modest, therefore, attenuated dosed three-drug combinations are investigated. We hypothesized that with adequate support a full dosed chemotherapy triplet is feasible. The study was designed as a dose finding study of paclitaxel in chemotherapy-naive patients. Paclitaxel was given as a 3-h infusion on day 1, followed by fixed doses of teniposide (or etoposide) 100 mg/m2 days 1, 3, 5 and cisplatin 80 mg/m2 day 1 every 3 weeks. As myelotoxicity was expected to be the dose-limiting toxicity, prophylactic G-CSF and antibiotic support was evaluated. Indeed, paclitaxel 120 mg/m2 resulted in dose-limiting neutropenia, despite G-CSF support. Teniposide/etoposide day 1, 3, 5 was less myelotoxic compared to day 1, 2, 3. G-CSF support allowed paclitaxel dose-escalation to 250 mg/m2. The addition of prophylactic antibiotics enabled dose-escalation to 275 mg/m2 without reaching MTD. In conclusion, G-CSF and antibiotics prophylaxis enables the delivery of a full dosed chemotherapy triplet in previously untreated NSCLC patients. 相似文献
112.
Bolster MJ Bult P Schapers RF Meijer JW Strobbe LJ van Berlo CL Klinkenbijl JH Peer PG Wobbes T Tjan-Heijnen VC 《Annals of surgical oncology》2006,13(11):1466-1473
Background Internationally, there is no consensus on the pathology protocol to be used to examine the sentinel lymph node (SN). At present, therefore, various hospitals use different SN pathology protocols of which the effect has not been fully elucidated. We hypothesized that differences between hospitals in SN pathology protocols affect subsequent surgical treatment strategies.Methods Patients from four hospitals (A–D) were prospectively registered when they underwent an SN biopsy. In hospitals A, B, and C, three levels of the SN were examined pathologically, whereas in hospital D, at least seven additional levels were examined. In the absence of apparent metastases with hematoxylin and eosin examination, immunohistochemical examination was performed in all four hospitals.Results In total, 541 eligible patients were included. In hospital D, more patients were diagnosed with a positive SN (P < .001) as compared with hospitals A, B, and C, mainly because of increased detection of isolated tumor cells. This led to more completion axillary lymph node dissections in hospital D (66.3% of patients (P < .0001), compared with 29.0% in hospitals A, B, and C combined). Positive non-SNs were detected in 13.9% of patients in hospital D, compared with 9.7% in hospitals A, B, and C (P = .70). That is, in 52.4% of patients in hospital D, a negative completion axillary lymph node dissection was performed, compared with 19.3% of patients in hospitals A, B, and C combined.Conclusions Differences in SN pathology protocols between hospitals do have a substantial effect on SN findings and subsequent surgical treatment strategies. Whether ultrastaging and, thus, additional surgery can offer better survival remains to be determined. 相似文献
113.
Bult P Tjan-Heijnen VC van Krieken H 《Nederlands tijdschrift voor geneeskunde》2006,150(26):1481; author reply 1481-1481; author reply 1483
114.
Verhagen AF Bollen E Tjan-Heijnen VC Bootsma GP Hensens A Oyen WJ 《Nederlands tijdschrift voor geneeskunde》2004,148(18):908; author reply 908-908; author reply 909
115.
Manders P Tjan-Heijnen VC Span PN Grebenchtchikov N Geurts-Moespot A van Tienoven DT Beex LV Sweep FC 《Cancer》2004,101(3):486-494
BACKGROUND: The ability of a solid tumor to grow and metastasize has a significant dependence on protease systems, such as the plasminogen activation system. The plasminogen activation system includes the urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1), among other molecules. Both uPA and PAI-1 are established prognostic factors for patients with breast carcinoma. In the current study, the authors investigated whether the complex of uPA with PAI-1 is also associated with the natural course of this malignancy. METHODS: Cytosolic levels of uPA, PAI-1, and the uPA:PAI-1 complex were measured in tumor tissue from 576 patients with lymph node-negative invasive breast carcinoma using quantitative enzyme-linked immunosorbent assays. Patients did not receive adjuvant systemic therapy, and the median follow-up duration was 61 months (range, 2-187 months) after primary diagnosis. Correlations with well known clinicopathologic factors were assessed, and univariate and multivariate survival analyses were performed. RESULTS: uPA:PAI-1 complex levels were positively associated with adverse histologic grade and inversely correlated with estrogen and progesterone receptor status. On univariate analysis, increased levels of the uPA:PAI-1 complex were found to be associated with reduced recurrence-free survival (RFS) and overall survival (OS) rates. On multivariate analysis, uPA:PAI-1 complex levels were found to be an independent predictor of OS (P = 0.039), but not RFS (P = 0.240). When uPA and PAI-1 levels were not included in the multivariate analysis, uPA:PAI-1 complex levels became a significant predictor of both RFS and OS (P = 0.029 and P = 0.007, respectively). CONCLUSIONS: The results of the current study demonstrate that uPA:PAI-1 complex levels have prognostic value on univariate analysis. In addition, increased uPA:PAI-1 complex levels were significantly associated with poor OS on multivariate analysis. Increased uPA:PAI-1 complex levels were also significantly associated with reduced RFS rates after the exclusion of uPA and PAI-1 levels from the multivariate analysis model. 相似文献
116.
Survivin is an independent prognostic marker for risk stratification of breast cancer patients 总被引:29,自引:0,他引:29
Span PN Sweep FC Wiegerinck ET Tjan-Heijnen VC Manders P Beex LV de Kok JB 《Clinical chemistry》2004,50(11):1986-1993
117.
Kramer GW Legrand CL van Schil P Uitterhoeve L Smit EF Schramel F Biesma B Tjan-Heijnen V van Zandwijk N Splinter T Giaccone G van Meerbeeck JP;EORTC-Lung Cancer Group 《European journal of cancer (Oxford, England : 1990)》2006,42(10):1391-1398
The aim of this study was to investigate the improvement of quality of radiotherapy and compliance to the protocol amendment of EORTC study 08941. The radiotherapy-specific data were analysed from 154 patients with stage IIIA-N2 Non-Small-Cell Lung Cancer who were actually irradiated after response to 3 cycles of platinum-based induction chemotherapy. The parameters of quality, assessed in 93 patients before and in 61 after protocol amendment, included: time interval between last chemotherapy course and start of thoracic radiotherapy, the use of a 3-D planning CT, dose and fractionation scheme to the primary tumour, the involved and uninvolved mediastinum, duration of radiotherapy and toxicity. A significant improvement of all quality parameters was noted, except for the overall treatment time, which decreased slightly. Protocol amendment resulted in an improvement of the quality and the compliance of most observed parameters, at the cost of some increase in overall treatment time. The latter reflects logistical problems rather than poor compliance. 相似文献
118.
119.
120.
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success 总被引:3,自引:0,他引:3
Span PN Lindberg RL Manders P Tjan-Heijnen VC Heuvel JJ Beex LV Sweep CG 《The Journal of pathology》2004,202(4):395-402
Tissue inhibitors of matrix metalloproteinase (TIMPs) may be involved in tumour growth, apoptosis, angiogenesis, invasion, and the development of metastases. This study has evaluated the association of the expression levels of the TIMP forms 1, 2, 3, and 4, measured by quantitative real-time RT-PCR, with classical clinicopathological characteristics, ie age, menopausal status, tumour size, histological grade, number of involved lymph nodes, and steroid hormone receptor status, and with disease progression and treatment sensitivity in 273 breast cancer patients. The mRNA levels of TIMP-1 and TIMP-2 were not associated with any known clinicopathological tumour feature. TIMP-3 and TIMP-4 levels were significantly higher in steroid hormone receptor-positive samples, although the levels of TIMP-4 were much lower than those of the other TIMPs. Only TIMP-3 predicted relapse-free survival (RFS) time differently depending on post-surgical treatment as, in particular, the interaction of TIMP-3 with endocrine therapy (p = 0.008, HR = 0.24, 95% CI = 0.09-0.69) contributed significantly to RFS in multivariate Cox regression analysis. In subgroup analyses, the 107 patients treated with tamoxifen differed greatly in prognosis after dichotomization by the median TIMP-3 level (p = 0.0003). Thus, high tumour levels of the matrix metalloproteinases inhibitor and pro-apoptotic factor TIMP-3 are associated with successful tamoxifen treatment of patients with breast cancer. 相似文献